NCT07188246 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07188246
Title	Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer (BRINK)
Acronym	BRINK
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Indications	Her2-receptor positive breast cancer invasive ductal carcinoma triple-receptor negative breast cancer
Therapies	Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	CAN

Facility	Status	City	State	Zip	Country	Details
St. Joseph's Health Care London		London	Ontario	N6A 4V2	Canada	Details
London Regional Cancer Program		London	Ontario		Canada	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07188246Clinical Trial Detail